The Board follows, as far as practicable, the recommendations in the Corporate Governance Code for Small and Mid-size Quoted Companies published by the QCA. As an Israeli company, the Company also complies with the corporate governance provisions of Israel’s Companies Law, 5759-1999
The Board is responsible to shareholders for effective direction and control of the Group and this report describes the framework for corporate governance and internal control that the directors have established to enable them to carry out this responsibility. As an AIM listed company, the Company is not required to comply with the provisions of the UK Corporate Governance Code (the “Code”) and this is not a statement of compliance as required by the Code. However, the Directors recognise the importance of sound corporate governance and, accordingly, comply with the Code, to the extent they believe appropriate for a company of its nature and size. The Board also follow, as far as practicable, the recommendations in the Corporate Governance Code for Small and Mid-size Quoted Companies published by the QCA in May 2013 (the “QCA Guidelines”), which have become a widely recognised benchmark for corporate governance of small and mid-size quoted companies, particularly AIM companies. As an Israeli company, the Company also complies with the corporate governance provisions of Israel’s Companies Law, 5759-1999 (the “Companies Law”).
The Board and Committees
The Board is responsible for the overall strategy and financial performance of the Group and has a formal schedule of matters reserved for its approval. Each Board meeting is preceded by a clear agenda and any relevant information is provided to directors in advance of the meeting. The Company has established properly constituted audit, remuneration and nomination Committees of the Board (in accordance with the Companies Law) with formally delegated duties and responsibilities. Terms of reference for each of these committees can be found on the Company’s website (www.plus500.com).
An evaluation of Board performance is assessed on an annual basis via questionnaire and detailed board discussion.
The Board also holds regular telephone calls to update the members on operational and other business. An agreed procedure exists for directors in the furtherance of their duties to take independent professional advice. Newly appointed directors are to be made aware of their responsibilities through the company secretary. The Company provides training to directors where required. No individual or group of directors dominates the Board’s decision making. Collectively, the nonexecutive directors bring a valuable range of expertise in assisting the Group to achieve its strategic aims. Since the Company’s admission to the AIM in July 2013, the roles of chairman and chief executive officer have been separate. The chairman is responsible for the effective running of the Board and the chief executive is ultimately responsible for all operational matters and the financial performance of the Group.
In accordance with the Companies Law, the Board must always have at least two External Directors who meet certain statutory requirements of independence. The Company’s External Directors are currently Charles Fairbairn and Daniel King. The term of office of an External Director is three years, which can be extended for two additional three year terms. Under the Companies Law, External Directors are elected by shareholders by a special majority and may be removed from office only in limited cases. Any committee of the Board must include at least one External Director and the Audit Committee and Remuneration Committee must each include all of the External Directors (including one External Director serving as the chair of the Audit Committee and Remuneration Committee), and a majority of the members of each of the Audit Committee and Remuneration Committee must comply with the director independence requirements prescribed by the Companies Law.
The Remuneration Committee has responsibility for determining, within the agreed terms of reference, the Group’s policy on the remuneration packages of the Company’s chief executive, the chairman, the executive and non-executive directors, the Company secretary and other senior executives. The Remuneration Committee also has responsibility for: (i) recommending to the Board a compensation policy for directors and executives and monitoring its implementation; (ii) approving and recommending to the Board and the Company’s shareholders, the total individual remuneration package of the chairman, each executive and non-executive director and the chief executive officer (including bonuses, incentive payments and share options or other share awards); and (iii) approving and recommending to the Board the total individual remuneration package of the Company secretary and all other senior executives (including bonuses, incentive payments and share options or other share awards), in each case within the terms of the Group’s policy and in consultation with the chairman of the Board and/or the chief executive officer. No Director or manager may be involved in any discussions as to their own remuneration.
The Remuneration Committee comprises Daniel King, Penelope Judd and Charles Fairbairn and is chaired by Daniel King and operates under written terms of reference.
The nomination Committee has responsibility for reviewing the structure, size and composition (including the skills, knowledge and experience) of the Board, and giving full consideration to succession planning. It also has responsibility for recommending new appointments to the Board.
The Nomination Committee comprises Daniel King, Gal Haber and Charles Fairbairn and is chaired by Daniel King. In accordance with the Companies Law, the term of office of Charles Fairbairn and Daniel King, the Company’s External Directors, continues until July 2016, and they will also be standing for re-election at the forthcoming Annual General Meeting and all committee members were present. Gal Haber did not participate in the meeting of the Nomination Committee concerning the proposal to re-nominate him for election to the Board. The Nomination Committee’s members believe that the directors put forward for re-election at the forthcoming Annual General Meeting continue to be effective and demonstrate commitment to their role. The Nomination Committee and Board unanimously recommend the re-election of all Board members offering themselves for re-election.
The Audit Committee has responsibility for ensuring that the financial performance of the Group is properly reported on and reviewed, and its role includes monitoring the integrity of the financial statements of the Group (including annual and interim accounts and results announcements), reviewing internal control and risk management systems, reviewing any changes to accounting policies, reviewing and monitoring the extent of the non-audit services undertaken by external auditors and advising on the appointment of external auditors. In addition, under the Companies Law, the Audit Committee is required to monitor deficiencies in the administration of the Company, including by consulting with the internal auditor and independent accountants, to review, classify and approve related party transactions and extraordinary transactions, to review the internal auditor’s audit plan and to establish and monitor whistle-blower procedures.
The Audit Committee comprises Charles Fairbairn, Penelope Judd and Daniel King, and is chaired by Charles Fairbairn. The committee operates under written terms of reference and meets at least twice a year with the Company’s external auditors, and with the executive directors present by invitation only. The committee meets with the external auditors without the executive directors present as it considers appropriate.
Regulatory and Risk Committee
The Regulatory and Risk Committee is chaired by Penelope Judd and its other members are Charles Fairbairn, Elad Even-Chen and Asaf Elimelech.
The Regulatory and Risk Committee is expected to meet not less than twice a year and otherwise as required. The Regulatory & Risk Committee has responsibility for reviewing relationships with the regulatory authorities and reviewing the adequacy and quality of the Group’s systems and procedures for compliance with regulatory requirements where the Group is regulated and in other jurisdictions where the Group has a significant presence. The Regulatory and Risk Committee also has responsibility for reviewing the Company’s most significant risks to the achievement of strategic objectives, review the Company’s risk policy, ensure that the Company’s board ethics are being adhered to and the Company continues its commitment to issues concerning social responsibility. The type of most significant risks and uncertainties are outlined herein.
Conflicts of Interest
The Company has procedures for the disclosure and review of any conflicts, or potential conflicts, of interest in compliance with the Companies Law, which the directors may have and for the authorisation of such conflict matters by the Board.
Under the Companies Law, any transaction of the Company with a director or any transaction of the Company in which a director has a personal interest requires the approval of the Board. The transaction must not be approved if it is adverse to the Company’s interest. If the transaction is an extraordinary transaction (i.e. a transaction that is not in the ordinary course of business, that is not on market terms or that is likely to have a material impact on a company’s profitability, assets or liabilities), then Audit Committee approval is required in addition to Board approval. If the transaction concerns exculpation, indemnification, insurance or compensation of the director, then the approvals of the Remuneration Committee, the Board and the shareholders by way of ordinary resolution are required (in that order). A director who has a personal interest in a matter that is considered at a meeting of the Board, the Audit Committee or the Remuneration Committee may not attend that meeting or vote on that matter, unless a majority of the Board, the Audit Committee or the Remuneration Committee, as applicable, has a personal interest in the matter. If a majority of the Board, the Audit Committee or the Remuneration Committee, as applicable, has a personal interest in the transaction, the shareholder approval, by way of ordinary resolution, is also required.
The authorisation of a conflict matter, and the terms of authorisation, may be reviewed at any time by the Board. The Board considers that these procedures are operating effectively. There have been no matters arising requiring assessment by the board as a potential conflict during the year.
Relationship with Shareholders
The Company encourages the participation of both institutional and private investors. The Chief Executive Officer, Mr. Asaf Elimelech, and Chief Financial Officer, Mr. Elad Even-Chen, meet regularly with institutional investors, usually in regard to the issuance of half and full year results. Communication with private individuals is maintained through the Annual General Meeting and the Company’s annual and interim reports. The chairmen of the Company’s audit, remuneration and nomination Committees are made available to answer questions at the Company’s Annual General Meetings. In addition, further details on the strategy and performance of the Company can be found at its website (www.plus500.com), which includes copies of the Company’s press releases. Regular updates are provided to the Board on meetings with shareholders and analysts, and broker’s opinions are made available to the Board. Non-executive directors are available to meet major shareholders, if required. Investors are encouraged to contact the Company’s Investor Relations, at ir@Plus500.com.